Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Intellia Therapeutics, Inc. or Beam Therapeutics Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Intellia Therapeutics, Inc. and Beam Therapeutics Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Intellia Therapeutics, Inc. and Beam Therapeutics Inc.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Latest Biotechnology and Intellia Therapeutics, Inc., Beam Therapeutics Inc. Stock News

As of May 12, 2026, Intellia Therapeutics, Inc. had a $2.0 billion market capitalization, compared to the Biotechnology median of $274.8 million. Intellia Therapeutics, Inc.’s stock is up 56.3% in 2026, up 1.4% in the previous five trading days and up 72.29% in the past year.

Currently, Intellia Therapeutics, Inc. does not have a price-earnings ratio. Intellia Therapeutics, Inc.’s trailing 12-month revenue is $66.1 million with a -597.0% net profit margin. Year-over-year quarterly sales growth most recently was -9.6%. Analysts expect adjusted earnings to reach $-3.305 per share for the current fiscal year. Intellia Therapeutics, Inc. does not currently pay a dividend.

As of May 12, 2026, Beam Therapeutics Inc. had a $3.1 billion market cap, putting it in the 61st percentile of all stocks. Beam Therapeutics Inc.’s stock is up 13.3% in 2026, down 2.9% in the previous five trading days and up 81.39% in the past year.

Currently, Beam Therapeutics Inc. does not have a price-earnings ratio. Beam Therapeutics Inc.’s trailing 12-month revenue is $164.0 million with a -40.2% net profit margin. Year-over-year quarterly sales growth most recently was 322.7%. Analysts expect adjusted earnings to reach $-4.479 per share for the current fiscal year. Beam Therapeutics Inc. does not currently pay a dividend.

How We Compare Intellia Therapeutics, Inc. and Beam Therapeutics Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Intellia Therapeutics, Inc. and Beam Therapeutics Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Intellia Therapeutics, Inc. and Beam Therapeutics Inc. Stock Value Grades

Company	Ticker	Value
Intellia Therapeutics, Inc.	NTLA	F
Beam Therapeutics Inc.	BEAM	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Intellia Therapeutics, Inc. has a Value Score of 9, which is Ultra Expensive. Beam Therapeutics Inc. has a Value Score of 9, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Intellia Therapeutics, Inc. or Beam Therapeutics Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Intellia Therapeutics, Inc. or Beam Therapeutics Inc. is the better investment when it comes to value.

Intellia Therapeutics, Inc. and Beam Therapeutics Inc.’s Quality Grades

Company	Ticker	Quality
Intellia Therapeutics, Inc.	NTLA	D
Beam Therapeutics Inc.	BEAM	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Intellia Therapeutics, Inc. has a Quality Score of 24, which is Weak. Beam Therapeutics Inc. has a Quality Score of 21, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither Intellia Therapeutics, Inc. or Beam Therapeutics Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Intellia Therapeutics, Inc. or Beam Therapeutics Inc. is the better investment when it comes to quality.

Intellia Therapeutics, Inc. and Beam Therapeutics Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Intellia Therapeutics, Inc.	NTLA	B
Beam Therapeutics Inc.	BEAM	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Intellia Therapeutics, Inc. has a Earnings Estimate Score of 67, which is Positive. Beam Therapeutics Inc. has a Earnings Estimate Score of 54, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Intellia Therapeutics, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Intellia Therapeutics, Inc. has a better Earnings Estimate Revisions Grade than Beam Therapeutics Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Intellia Therapeutics, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Intellia Therapeutics, Inc. and Beam Therapeutics Inc. Grades

In addition to Estimate Revisions, Quality and Value, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Intellia Therapeutics, Inc. and Beam Therapeutics Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Intellia Therapeutics, Inc. or Beam Therapeutics Inc. Stock?

Overall, Intellia Therapeutics, Inc. stock has a Value Score of 9, Estimate Revisions Score of 67 and Quality Score of 24.

Beam Therapeutics Inc. stock has a Value Score of 9, Estimate Revisions Score of 54 and Quality Score of 21.

Comparing Intellia Therapeutics, Inc. and Beam Therapeutics Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.